Name | Niflumic acid |
Synonyms | Niflumic acid ACIDUM NIFLUMICUM Niflumic acid solution,100ppm ACIDUMNIFLUMICUM(NIFLUMICACID) Nicotinic acid Solution, 100ppm 2-[3-(Trifluoromethyl)anilino]nicotinic acid 2-(α,α,α-trifluoro-m-toluidino)nicotinic acid 2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid 2-[3-(Trifluoromethyl)-phenyl]aminonicotinic acid 2-(alpha,alpha,alpha-trifluoro-m-toluidino)nicotinic acid 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylate 2-[(3-Trifluoromethylphenyl)amino]nicotinic AcidNiflumic Acid 2-[3-(Trifluoromethyl)anilino]nicotinic acid, 2-(α,α,α-Trifluoro-m-toluidino)nicotinic acid |
CAS | 4394-00-7 |
EINECS | 224-516-2 |
InChI | InChI=1/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)/p-1 |
InChIKey | JZFPYUNJRRFVQU-UHFFFAOYSA-N |
Molecular Formula | C13H9F3N2O2 |
Molar Mass | 282.22 |
Density | 1.3935 (estimate) |
Melting Point | 203-204 °C |
Boling Point | 378.0±42.0 °C(Predicted) |
Flash Point | 182.4°C |
Water Solubility | 19mg/L(room temperature) |
Solubility | Soluble in ethanol (~50 mg/ml), acetone (50 mg/ml, Clear to Slightly Hazy, Yellow), methanol (~50 mg/ml), DMSO (56 mg/ml at 25°C), and acetonitrile (~50 mg/ml). |
Vapor Presure | 2.18E-06mmHg at 25°C |
Appearance | Bright yellow crystal |
Color | Light orange to Yellow to Green |
Merck | 14,6531 |
pKa | pKa 2.26 ± 0.08;4.44± 0.03(H2O,t =25±0.1,I=0.01(NaCl))(Approximate) |
Storage Condition | 2-8°C |
Stability | Stable, but may discolour in light. Incompatible with strong oxidizing agents. Hygroscopic. |
Sensitive | Light Sensitive |
MDL | MFCD00010569 |
Use | Used as a pharmaceutical Intermediate |
In vitro study | Niflumic acid inhibits Calcium-activated chloride channels with an inhibition constant of 17 mM. Niflumic acid can also inhibit ICl (CA) caused by calcium ions. Calcium ions enter oocytes through ionophore A23187, indicating that the inhibition of ICl (CA) is due to the direct combination with chloride ion channels, rather than by interference through voltage-dependent calcium channels. In the basolateral membrane of rat pancreatic exocrine cells, Niflumic acid inhibits calcium ion activation with an IC 50 of 50 μm. Niflumic acid dose-dependently and reversibly activates Calcium-activated kryptine (KCa) channels. Niflumic acid produces the amplitude of an inward current (STIC, Calcium-activated chloride current) of spontaneous transient concentration-dependent inhibition. Niflumic acid inhibited IO(Ca) evoked by noradrenaline and caffeine with an IC50 of 6.6 μm, which was weaker than the current evoked by spontaneous currents. Niflumic acid voltage-dependent suppression of spontaneous transient current (STIC) amplitude, with IC50 of 2.3 μm and 1.1 μm at -50 mV and 50 mV, respectively. Niflumic acid not only inhibits IL-13-induced goblet cell hyperplasia, but also inhibits airway hyperresponsiveness and eosinophil invasion. After IL-13 instillation, Niflumic acid inhibited chemokine levels in bronchoalveolar lavage fluid and overexpression of the MUC5AC gene, MUC5A a marker of goblet cell hyperplasia. Niflumic acid inhibits JAK2 activation, STAT6 activation, and chemokine expression in epithelial cells. |
Hazard Symbols | Xn - Harmful |
Risk Codes | R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
UN IDs | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | QT2999100 |
HS Code | 29333999 |
Hazard Class | 6.1 |
Packing Group | Ⅲ |
Toxicity | LD50 in rats (mg/kg): 370 orally; 155 i.p. (Sorenson) |
NIST chemical information | Information provided by: webbook.nist.gov (external link) |
EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
pharmacological effects | niflumic acid is a non-steroidal anti-inflammatory and analgesic drug. Different dosage forms and routes of administration have shown anti-inflammatory, analgesic and detumescence effects in animal experiments. It has been widely used in clinical studies that it has low toxicity, good tolerance, and better curative effect than other anti-inflammatory and analgesic drugs. This product does not cause sodium retention and can be used in elderly patients. |
biological activity | Niflumic acid is a cyclooxygenase-2 (COX-2) inhibitor used to treat joint and muscle pain. |
Target | Value |
use | as a pharmaceutical intermediate |